| NCT05589610 | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | COMPLETED | PHASE2 | 2022-12-19 | 2024-04-30 | 2024-03-26 |
| NCT05263999 | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) | TERMINATED | PHASE3 | 2022-04-29 | 2025-05-12 | 2025-04-22 |
| NCT03532958 | Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata | WITHDRAWN | PHASE2 | 2021-10 | 2022-11 | 2022-11 |
| NCT04605926 | A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19 | WITHDRAWN | PHASE3 | 2020-11 | 2021-06 | 2021-04 |
| NCT04128579 | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | COMPLETED | PHASE1 | 2019-10-01 | 2024-01-18 | 2023-11-16 |
| NCT03763318 | A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD | COMPLETED | PHASE1, PHASE2 | 2019-07-15 | 2022-11-21 | 2022-11-21 |
| NCT04007198 | A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma | COMPLETED | PHASE1 | 2019-06-20 | 2021-10-12 | 2021-10-12 |